MEDICINE PRICE GAP SPARKS POLITICAL FIRESTORM OVER INDIA’S HEALTHCARE COSTS

October 5, 2026

NEW DELHI — A sharp difference between the reported manufacturing cost and retail price of a medicine has triggered a fresh political confrontation over the affordability of healthcare in India.

The controversy centres on an injection reportedly costing around ₹74 to produce but being sold to patients for nearly ₹4,980. The figure has been cited by the Congress to question the government’s approach to regulating medicine prices and protecting patients from excessive treatment costs.

The Opposition party has accused the Centre of failing to adequately address the high prices of essential medicines and has argued that patients and families are being forced to bear an unfair financial burden during medical treatment.

The issue has also revived wider concerns over the pricing structure of pharmaceutical products in India, where the final price paid by a patient can include manufacturing costs, distribution expenses, taxes, margins and other commercial components.

For families dealing with serious illnesses, high-priced medicines can significantly increase the overall cost of treatment, particularly when drugs or injections have to be administered repeatedly over an extended period.

The political dispute comes amid continuing demands for stronger price regulation and greater transparency in the pharmaceutical sector. The controversy is likely to keep attention focused on how medicine prices are determined and whether existing mechanisms are sufficient to ensure affordable access to essential healthcare.

The episode has once again placed the question of affordable medicines versus pharmaceutical pricing and commercial margins at the centre of India's healthcare debate.